Log in to search using one of your social media accounts:

 

PSMA PET/CT clearly differentiates prostate cancer from benign tissue

(Society of Nuclear Medicine and Molecular Imaging) Using nuclear medicine, German researchers have found a way to accurately differentiate cancerous tissue from healthy tissue in prostate cancer patients. The research is highlighted in the February issue of The Journal of Nuclear Medicine and demonstrates that the maximum standardized uptake value (SUVmax) on 68Ga-PSMA PET/CT scans correlates with PSMA-expression in primary prostate cancer. By this means, researchers were able to generate an SUVmax cutoff for the differentiation of cancerous and benign prostate tissue.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news

Related Links:

ObjectivesTo improve imaging utilisation and reduce the widespread overuse of staging investigations, in the form of computed tomography (CT) and whole‐body bone scans for men with newly diagnosed prostate cancer in the Hunter region of NSW, Australia, by implementation of a multifaceted clinician‐centred behaviour change programme. Patients and MethodsRecords of all patients with a new diagnosis of prostate cancer were reviewed prior to the intervention (July 2014 to July 2015), and the results of this audit were presented to participating urologists by a clinical champion. Urologists then underwent focused education ...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
CONCLUSION: There was no difference between NaF PET/CT and BS in the detection of PD and non-PD; however, BS seemingly detects PD by the PCWG-2 criteria earlier than NaF-PET, which might be explained by the fact that NaF-PET is more sensitive at the baseline scan. PMID: 29447047 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Purpose The aim of this study was to assess the ability of fluorine-18-fluorocholine (18F-FCH) PET/computed tomography (CT) to detect oligometastatic disease (OMD) in patients with early recurrence of prostate cancer (PC) [prostate-specific antigen (PSA)≤5 ng/ml]. Patients and methods Between 2010 and 2016, 324 patients with PC and PSA levels of less than or equal to 5 ng/ml were recruited. The mean (SD) age of the patients was 71 (10) years. All patients were treated with a radical prostatectomy±lymphadenectomy. One-hundred and twenty-one patients were under hormonal therapy at the time of PET...
Source: Nuclear Medicine Communications - Category: Nuclear Medicine Tags: Original Articles Source Type: research
Treating oligometastases detected by [18F]-fluoromethylcholine positron-emission tomography/computed tomography (PET/CT) with stereotactic body radiotherapy (SBRT) may postpone initiation of androgen-deprivation therapy, and possibly prolong progression-free survival (PFS). However, better prognostic factors are needed to improve patient selection. We investigated the predictive value of [18F]-fluoromethylcholine-PET/CT-derived parameters on PFS in oligometastatic prostate cancer patients treated with SBRT.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
We present 18F-fluorocholine PET/CT imaging of prostate cancer with very rare lytic bone metastases.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
Abstract ObjectivesTo improve imaging utilisation and reduce the widespread overuse of staging investigations, in the form of computed tomography (CT) and whole body bone scan (BS), for men with newly diagnosed prostate cancer in the Hunter region of NSW, Australia by implementation of a multifaceted clinician‐centred behaviour change program. Subjects and methodsRecords of all men with a new diagnosis of prostate cancer were reviewed prior to intervention (July 2014‐July 2015), and results of this audit presented to participating urologists by a clinical champion. Urologists then underwent focused education based upon...
Source: BJU International - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Nonmetastatic castration-resistant prostate cancer (nmCRPC) presents a challenge to urologists as currently there are no Food and Drug Administration-approved therapies. However, there are new imaging modalities, including fluciclovine positron emission tomography-computed tomography and Ga-PSMA (prostate specific membrane antigent) positron emission tomography-computed tomography, which are improving accuracy of diagnosis. With improved imaging, we are better able to target therapy. Today there are 3 ongoing clinical trials studying second-generation antiandrogens in nmCRPC, which hold the promise of a new treatment paradigm.
Source: Urology - Category: Urology & Nephrology Authors: Tags: Review Article Source Type: research
68Ga-PSMA PET/CT scan on a 70-year-old man with recently diagnosed prostate cancer revealed a spiculating nodule in the apex of the left lung with intense 68Ga-PSMA uptake. The nodule had no pathological 18F-FDG uptake and turned out to be a primary adenocarcinoma of the lung. Cases with complementary pattern of uptake in 18F-FDG and 68Ga-PSMA in metastatic clear cell renal carcinoma and in well-differentiated hepatocellular carcinoma have previously been reported; however, this case illustrates that this unusual pattern can also be present in primary lung cancer.
Source: Clinical Nuclear Medicine - Category: Nuclear Medicine Tags: Interesting Images Source Type: research
We report a 65-year-old male with histopathologically proven prostate cancer and multiple pelvic node metastases using a robotic-assisted radical prostatectomy procedure plus extended pelvic lymph node dissection. Positron emission tomography (PET) scan findings demonstrated a moderate accumulation of11C-choline in a metastatic left obturator node sized 8 × 8 mm, though only a faint uptake of fluorodeoxyglucose (FDG) was noted.11C-choline PET/computed tomography (CT) may be useful for the diagnosis of a tiny metastatic lymph node not demonstrated by CT, magnetic resonance imaging, or FDG-PET/CT and to determine the n...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
r M Abstract Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resi...
Source: Der Radiologe - Category: Radiology Authors: Tags: Radiologe Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Germany Health | Nuclear Medicine | PET Scan | Prostate Cancer